AIDSWEEKLY Plus; Monday, December 29, 2003
Staff Medical Writers

Therefore, the company has now initiated a series of nonhuman primate studies to further validate its unique delipidation technology. The ultimate goal of these studies is the development of a therapeutic vaccine approach for use against HIV.

"Based on the excellent results we have seen in animal studies with mice, we have now moved our developmental program forward to nonhuman primates. This step is consistent with our strategic plan and is the next phase in the validation of our viral immunotherapy platform," noted Dr. S. Lewis Meyer, president and CEO of Lipid Sciences. He continued, "The final results of these nonhuman primate studies will enable the company to present data to the FDA [Food and Drug Administration] and discuss what additional preclinical animal testing, if any, might need to be completed before we move into a human clinical trial."

Lipid Sciences is a development-stage company engaged in the research and development of products and processes to treat major medical indications through its technology of lipid removal known as delipidation.

The mouse studies were conducted under the direction of Dr. Aftab A. Ansari, professor, department of pathology and laboratory medicine, Emory University School of Medicine. Ansari is a member of the Lipid Sciences' viral advisory board.

Ansari observed, "Lipid Sciences' delipidation process has resulted in a unique, optimized treatment that is highly effective, not only in delipidation, but also in reducing viral infectivity while appearing to retain a very high percentage of significant viral proteins. The delipidated virus has elicited an immune response against a distinct set of viral epitopes. The ability to respond to a broad array of antigens, exposed by the selective removal of the viral lipid coat, holds promise for the development of a novel autologous therapeutic vaccine for use in HIV patients."

This article was prepared by AIDS Weekly editors from staff and other reports.

031229
AW031215

Copyright © 2003 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright © 1980,2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.